Vertex Suffers Setback In Its Search For Post-CF Blockbusters
Analysts Doubt Pipeline Potential
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
You may also be interested in...
Hoping to bring a candidate for the alpha-1 disorder into the clinic in 2023, Korro’s latest funding is meant to enable development of a rare CNS disorder drug and a third drug for a more prevalent indication.
After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.